SEC Form 4 · accession 0001144204-15-011246
Aevi Genomic Medicine, Inc. · GNMX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Sol J Barer
Director
Period of report
Feb 19, 2015
Accepted (ET)
Feb 23, 2015 · 6:00 am EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001138776
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Feb 19, 2015 | P | 100,000 | $7.38 | A | 307,000 | D | |
| Common StockF2 | Feb 20, 2015 | P | 50,000 | $7.55 | A | 357,000 | D | |
| Common StockF3 | holding | — | — | — | 365,854 | I | By grantor retained annuity trust |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $7.21 to $7.50, inclusive. The reporting person undertakes to provide to Medgenics, Inc., any security holder of Medgenics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1) and (2) to this Form 4.
- F2The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $7.50 to $7.60, inclusive.
- F3By the Sol J. Barer 2013 Grantor Retained Annuity Trust No. IV.